Here at Tapemark, we are the foremost leaders and innovators for development and manufacturing in transdermal and oral thin film drug delivery. No, really, we are. We offer a fully-integrated solution. Our services include formulation, optimization, blending, coating, converting, primary packaging, secondary cartoning, and kitting to commercially manufacture transdermal and oral thin film drugs. We have successful experience with NDA, ANDA, and 505(b)2 FDA approvals including those for Schedule I controlled substances. As a team of subject matter experts and craftsmen, we nurture our client's pharmaceutical formulation, develop it, scale it, and guide it through the FDA approval process. Tapemark is comprised of pioneering chemists, researchers, and engineers. As world experts in transdermal and oral thin film drug delivery, we offer full project management services to keep projects ahead of milestones and never behind. Tapemark has significant experience launching NDA and ANDA drugs to offer our clients the most hands-on and successful partnership in the CDMO space. Tapemark is known for its superior, truly unmatched, state-of-the-art equipment. Since the beginning, our investment has been laser-focused on owning and operating a 150,000-square-foot facility that cannot be beat in the industry. We are devoted to the industry's brightest people and most advanced equipment. We know what works. We know what doesn't. And we know where we can innovate and deliver for efficient FDA approvals and progressive timelines. The Tapemark team is powered, staffed, and driven to help clients move faster, better, and with unrivaled quality to benefit the patient and improve compliance. Our pharmaceutical products perform in the clinic and surpass FDA standards. Tapemark is privately-held and based in West St. Paul, Minnesota, with multiple facilities in a campus environment. The company services the pharmaceutical, medical, and consumer products markets.